Rugg Elizabeth L
Department of Dermatology, University of California, Irvine, Irvine, California 92697, USA.
J Invest Dermatol. 2008 Jan;128(1):7-8. doi: 10.1038/sj.jid.5701065.
The identification of mutations in keratin genes as the cause of several inherited skin disorders raised the possibility that molecular-based therapies might be developed to treat these conditions. In this issue, Smith et al. (2007) have identified small interfering RNAs that specifically and potently silence keratin 6a expression. These molecules have great promise as therapeutic agents for the treatment of pachyonychia congenita.
角蛋白基因突变被认定为多种遗传性皮肤病的病因，这引发了一种可能性，即可能开发出基于分子的疗法来治疗这些病症。在本期中，史密斯等人（2007年）鉴定出了能特异性且强效沉默角蛋白6a表达的小干扰RNA。这些分子作为治疗先天性厚甲症的治疗药物具有很大的前景。
